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In theory, under strictly defined ideal conditions, the 
bioavailability of a drug from a topical formulation 
should depend only on the thermodynamic activity of 
the medicament in the base. We tested this fundamental 
postulate using a steroid as the test drug, formulated in 
a series of ' solutions and gels at 90% saturation, i.e., 
ideally at constant thermodynamic activity. The in vivo 
assessment method was the occluded vas()constrictor 
test in humans. For most systems, this simple measure 
of thermodynamic activity correlated with drug bioa-
vailability as assessed by the blanching response. Where 
there were differences, we have rationalized them in 
terms of penetration enhancement, irritancy, dehydra-
tion of the stratum corneum, or steroid binding in the 
base, although such factors have not been explicitly 
demonstrated. 
When modern formulators develop dermatologic prepara-
tions for optimum bioavailability, they employ two main meth-
ods of approach, either singly or combined. The first sch eme 
formulates the vehicle in such a way that the drug h as the 
maximum tendency to leave the base and to partition into the 
skin, with no intention that t he vehicle components should 
affect the physicochemical properties of the stratum corneum. 
Thus the vehicle design promotes drug release by simply optim-
izing the thermodynamic activity of the medicament. The al-
ternative method . of approach is to incorporate into the for-
mulation materials, known as penetration enhancers, i.e., chem-
icals which themselves permeate the skin, dynamically a nd 
reversibly decreasing the r esistance of the stratum corneum to 
the penetration of the drug. This paper discusses the thermo-
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dynamic approach and a second investigation reports on the 
effect of penetration enh ancers. 
The aim of this study therefore is to investigate the vasocon-
strictor activities and, by inference, the clinical anti- inflamma-
tory efficacies a nd bioava ilabilities of a range of optimized 
formulations of the topical steroid, mecWorosone dibutyrate. 
The bioassay employed is t h e occluded vasoconstrictor test [1-
4]. 
MATERIALS AND METHODS 
Six solutions (fu'st series) and 6 gels (second series) or the composi-
tion listed in Table I were used as received from Unilabo, France. In 
each of these systems, the solvent compositions had been adjusted so 
that the steroid was at 90% saturation, i.e., ideally at the same ther-
modynamic activity. This is a simplification as the chemical potential 
of a real system will depend on concentration in a different way for 
different nonideal systems. However, the assumption that all the for-
mulations at 90% saturation are at the same thermodynamic activ ity 
provides us with a starting point to examine any deviations. Betnovate 
cream (betamethasone as valerate, 0.1%) was used as a standard prep-
aration to control the vasoconstrictor test. 
Subjects 
Ten volunteers were selected; none had received topical cortico-
steroid application for at least two months prior to the study. 
Method 
Two trials were performed, one for the solu tions and one for the gels. 
Five microliters of each of the test solutions (or 5 .mg of each gel) and 
5 mg Betnovate cream were applied at sites on the washed flexor 
surface of each forearm. The application sites consisted of 7 x 7 mm 
areas punched-out from Blenderm tape, to which formu lations were 
applied using a random design. The sites were occluded with type S12 
/.1m Melinex film for 6 hr. Tapes and films were removed and the areas 
were washed with soap and water at body temperature and were dried. 
Readings were taken in a double-blind manner after 10 min and after 
1, 2, 3, 6, 18, 26, 42, 66, 74, and 90 hr to provide data points for skin 
blanching at 6, 7,8,9, 12, 24, 32. 48, 72, 80, and 96 hr after application. 
Assessment was made according to a 0-4 scale with half-point ratings 
for intermediate readings: 0 = normal skin, 1 = sligh t vasoconstriction 
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TABLE 1. Com.position of solutions and gels on % w/ w basis 
Prep'll Sl HG PG PEG PC W GS C T TD 
S 
A 0.2 14.0 85.8 
B 0.2 65.9 33.9 
C 0.2 58.5 14.6 26.7 
D 0.2 48.4 32.2 19.2 
E 0.2 69.6 17.4 12.8 
F 0.2 79.8 20.0 
G 
D 0.1 42.2 28.2 27.4 1.5 0.14 0.5 
E 0.1 62.7 15.7 19.6 1.25 0.14 0.5 
F 0.1 70.5 17.7 3.7 7.3 0.75 
D 0.2 47.4 31.6 18.7 1.5 0.14 0.5 
E 0.2 68.3 17.1 12.5 1.25 0.14 0.5 
F 0.2 70.7 21.1 7.3 0.75 
Abbreviations: St = steroid (mechlorosone dibu tyrate), HG = hexy-
lene glycol, PG = propylene glycol, PEG = polyethylene glycol 400 
(PEG 400) , PC = propylene carbonate, W = water, GS = gels, C = 
cal'bopol, T = triethanolamine, TD = titanium dioxide, S = solutions. 
of indistinct outline, 2 = more intense vasoconstriction, 3 = general 
even vasoconstriction wi th a clear outline of the squru'e, and 4 = more 
marked vasoconstriction wi th very distinct blanching. 
T en volun teers provided a total of 140 application sites. Total pos-
sible score for each prepal'ation: 4 per site, 8 per volun teer, 80 for 10 
volunteers, i.e., if, at any single t ime interval in the test, all the sites for 
a particular prepru'ation scored 4 on the above scale, the maximum 
tota l possible score would be 80. Actual results were expressed as the 
"percent tota l possible score" achieved at each time interva l. 
In order to assess the retention of steroid in the skin, the sites were 
occluded with water-impervious Melinex film for 12 hr, 8 days after 
commencement of the experiment. Pallor was estimated 5 hr later 
when blanching was maximal. As only 2 volunteers were used, the 
resul ts are only approximate and simply indicate the presence of a 
steroid reservoir. 
The data were submi tted to an analysis of vru'iance, which is used to 
compare more than 2 sample means [5]. 
A computer program analyzed the data wi thout transformation or in 
1 of 5 (x- ', x- l , log X, xl, arid x2) transfol'mations [6]. T est for nonaddi-
tivi ty [7] indicated that aU nonaddit ivity l' values were low, suggesting 
that selection of transformation is not important. The square roots 
transformation was therefore used as this had been employed in pre-
vious publications. T he analysis of vru'iance was calculated using these 
values. 
Calculation of the minimum significant range value by using the 
Studentized .range test [5J permitted compru'ison of the corticosteroid 
formulations. If the 1'111/10 mean values of two preparations (see T ables 
II and IV) differ by more than the minimum significance range value, 
k, there is a significant difference at the 5% level between these 
formulations. Thus the resul ts of the randomized block design variance 
analysis showed that there were significant di fferences ruTIong prepa- , 
rations. 
RESULTS AND DISCUSSION 
Fig 1 shows t h e vasoconstrictor profiles for t h e st eroid solu-
tions in terms of percen t total possible scor e vs . time axes. For 
clarity , experimental points were omitted but they aU lay on or 
near the curves as drawn. The accUl"acy of t his pj'ocedw'e h as 
been a mply demonstra ted previously [3,4]. To compar e th e 
differ ent steroid so lutions we used 3 m ain param eters (Table 
II) : (a ) The summed percent total possible score, i.e ., the 
per centage of th e total possible Scores summed for all volu nteers 
over a ll reading times. (b) Square root transformat ion of t h e 
sum of scores divided by t h e number of volunteers; th e solut ions 
m ay t h en be r anked s tatistically in order of pharmacologic 
activity . (c ) E s timation of t h e actual ar ea under the blan ching 
curve. 
Table III illustr a tes t wo ways of assessing t h e compar ative 
bioavaila bilities of t he st eroid fTom th e test solutions. The term 
" bioava ila bility" is used h ere to refer to the r ela tive absorption 
eff iciency for a stero id as d etermined by its release fr om th e 
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FIG 1. Blanching curves (percent total possible score vs. time) for 
0.2% steroid solutions of composition listed in Ta ble I, and for Betno-
vate cream (0.1% betamethasone 17-valerate) used as a control. The 
curves are drawn from the mean responses for duplicate applications to 
the arms of 10 volunteers. For preparations A-F, only E was signifi-
cantly more active than the others (p = 0.05). 
TABLE II. Blanching responses to 0.2% steroid solutions, a.rranged 
in ranh order of a.rea under the curve values" 
Area under Summed % Tm/ 1O % Tolal possible Solu tion the curve" (% lolal possible mean 
x hour) score'- vaJu e,1 score on reocclusion" 
E 2650 413 5.72 34 
A 2140 345 5.23 34 
B 2080 339 5.18 31 
D 1910 305 4.92 34 
F 1780 265 4.59 25 
C 1720 282 4.73 28 
Betnovate 2280 393 28 
CreruTI 
" For compositions, see Table 1. 
b Obtained by planimetry of the blanching profIle. 
C The corrected % total possible score summed for aU volunteers over 
aU reading times. 
d The Tm/ 10 mean value is the square root transformation of sum of 
,scores (.\fm) divided 'by the number of volunteers (10). T he minimum 
significant range value k = 0.28 (p = 0.05), i.e. , if the Tm/ 10 values of 
two prepru'ations differ"by more ·t han 0.28 there is a significant differ-
ence 'betw,eeTh those prepru·ations. 
r Reoocluded for "l.2-hr, 8 days after commencement of the experiment 
(2 vo[.unteel·s;·.statistical treatment inapplicable). 
prepar ation, followed by its penetration throu gh th e epidermis 
into t h e dermis to produce t h e ch aracteristic blan ch ing effect. 
It is accep ted that a knowledge of t h e t ime of onset, intensity, 
duration , and d ecline of cor t icosteroid -induced pallor may be 
used to assess both the activity of a steroid an d its bioavaila-
bility from differ en t vehicles, as m easured by a pharmacologic 
response [3]. 
Fig 2 shows th e blan ching profiles for t h e gels, with analysis 
data in T able IV a nd bioavailabili ty assessmen ts in Table V. 
In considering t h e t h eory r elevan t to t h ermodynamic control 
of percu taneous a bsorpt ion , we start wit h t h e assu m p t ion th at ' 
the stratum corneum provides t h e rate-limiting step in th e 
overall process of percu taneous a bsorption . T his procedUl"e is 
t h e sequence of even ts dur ing which th e drug leaves th e applied 
vehicle, par t it ions into th e skin, an d diffuses tlu-ough t h e tissues 
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T ABL E III. Blanching responses to 0.2% steroid solu.tions expressed 
in bioavailability term.s to establish bioequ.ivalence" 
(i) 
Solu tion Bioavailabili ty" (i) 
E 1.00 
A 0.81 
B 0.79 
D 0.72 
F 0.67 
C 0.65 
" For compositions, see Table 1. 
"Defin ed by the relationships 
"area under the cUl"ve" for solution 
"area under the curve" for most active 
solution (solution E) 
(ii) summed % total possible score for solution 
summed % total possible score for most active 
solution (solution E) 
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FIG 2. Blanching curves (percent total possible score vs. t ime) for 
0.1% and 0.2% steroid gels of composition listed in Table I, and for 
Betnovate cream (0.1.% betamethasone 17-valerate) used as a control. 
T he CUl"Ves ru'e drawn from the mean responses for duplicate applica-
tions to the arms of 10 volunteers. Wi thin any solvent system (D, E , or 
F) thel'e was no significant diffe rence among gels that contained 
different concentrations of steroid (0.1.% or 0.2%) (p = 0.05). 
to be finally rem oved 'via the systemic circu lation. Poulsen [8] 
has discussed in detail how the flux of a drug through the skin 
m ay ch a nge when the solubilizing power of the vehicle for the 
drug alters in specific ways. The relevant model analysis as-
sumes the following (condit ions particularly relevant to the 
present study are marked with an' asterisk): (i *) The horny 
layer of the skin provides the ra te-limiting step in per cutaneous 
absorption. (ii) The skin forms a homogeneous, intact mem-
brane. (iii*) The drug species behaves ideally, is nonionic, and 
is una ffected by ch a nges in the pH of the vehicle. (iv*) Only 
the drug diffuses; formula tion components neither diffuse nor 
Vol. 79, No.6 
TABLE IV . Blanching re:>ponses to steroid gels, arranged in. ranh 
order of area u.nder the curve values" 
Area under Summed % Tm/ IO % Total possi-
Gel the curve" (% total possi- mean ble score on 
x hour) ble scoree va lu e" reocclusion" 
Type E 0.2% 2430 412 5.68 34 
Type E 0.1 % 2240 380 5.48 34 
Type 1" 0.2% 2220 331 5.10 22 
Type D 0.2% 2020 336 5. 14 25 
Type F 0.1% 1890 304 4.90 16 
Type D 0.1 % 1590 281 4.71 22 
Betnovate cream 1920 393 5.58 22 
" For compositions, see Table I. 
b Obtained by planimetry of the blanching prof Li e. 
,. The corrected % total possible score summed for all volunteers over 
all reading times. 
d The Tm/ 1O mean value is the squru'e root transformation of sum of 
scores (1'm) divided by the number of volun teers (10) . The minimum 
significance range value k = 0.58 (p = 0.05), i.e., if the Tm/ 1O values of 
two preparations differ by more than 0.58 there is a significant differ-
ence between those preparations. 
,. Reoccluded for 12 hI', 8 days after commencement of the experiment 
(2 volunteers; sta tistical treatment inapplicable). 
TABLE V. Blanching resp onses to steroid gels expressed in 
bioavailability term.s to estcLblish bioequivalence" 
Gel Biollvailabili ty" (i) 
0.2% Steroid 
Type E 1.00 
Type F 0.91 
Type D 0.83 
0.1% Steroid 
(i) 
Type E 1.00 
Type F 0.84 
Type D 0.71 
" For compositions, see Table 1. 
b Defin ed by the rela tionships 
"ru'ea under the curve" for gel 
"area under the curve" for most 
active gel (Type E) 
(ii) summed % total possible score for gel 
summed % total possible score for most 
active gel (Type E) 
(ii) 
1.00 
0.80 
0.82 
1.00 
0.80 
0.74 
evaporate s ignificantly and skin secretions do not alter the 
vehicle. (v) The diffusion coefficient of t he penetrant is invar-
iant with time or position within the vehicle or in the horny 
layer. (vi) Neither the vehicle nor the penetrant changes the 
diffusion coefficient within the horny layer during ' the absorp-
tion process. (vii) P enetrant reaching the viable tissues imme-
diately sweeps into the systemic circula tion, so that sink con-
ditions exist below the stratum corneum. (viii) The donor p'hase 
does not dep let e during the diffusion process, i.e., the drug 
concentra tion in the vehicle is constant. (ix*) The vehicle does 
not damage the skin or othel\wise alter its permeabili ty during 
a n experiment. (x) The drug re mains unalter ed and intact . (xi) 
Flux estimates are s teady-state ·values. 
Under the a bove set of restrictions, workers ofte n use the 
diffusional model of simple s teady-state flux defined by: 
dM KCD 
Tt=-h- (1) 
where dM/ dt is the s teady-state flux of penetrant per unit aj'ea 
of membrane; K is the partition coefficient of the dl"Ug between 
the horny layer and the vehicle; C is the concentration of drug 
dissolved in the vehicle; D is th e diffusion coefficient of the 
drug in the horny layer; h is the thickness of this layer . 
However, a n alterna tive way to consider the r elationship 
defin ed in equa tion (1) is to express it in terms of thermody-
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namic activities [9]: 
dM aD 
dt yh 
(2) 
where a is the thermodynamic activity of the drug in its vehicle 
and y is the effective activity coefficient of the drug in the skin 
barrier phase. 
If we generalize this relationship with respect to time, we see 
that, under the conditions outlined previously, the dl·ug flux 
should be directly proportional to the thermodynamic activity 
in the vehicle. Thus, we should achieve the same flux from all 
vehicles in which the thermodynamic activity is the same, 
whatever the actual concentration of the drug. In other words, 
the tendency of the drug to escape from the vehicle and to 
enter the skin should be the same. This is the condition delib-
erately formulated for each preparation in the present study. 
The vasoconstrictor test, originally introduced to screen novel 
synthetic steroids in alcoholic solution [10], can also be used to 
aid the development of topical formulations, to test marketed 
products and rank them in terms of clinical efficacy, to develop 
dosage regimens for topical steroids, and, as in this paper, to 
perform fundamental studies on percutaneous absorption [4]. 
The assumption is made that the extent of blanching correlates 
directly with the bioavailability of the steroid, i.e., the relative 
extent of drug release from a preparation and its penetration 
into the skin. 
If we consider first the results of the tests on the solutions 
(Fig 1) we see that all the preparations produced obvious 
blanching; the shapes of the curves are characteristic similar 
to each other, and they resemble curves produced by ~ variety 
of poten~ s,teroid form~lations (e.g., [1-4]). The rankings of the 
preparatlOns, based either on area under the curve values or 
summed percent total possible scores, were alike (Table II) . 
Bioavailability values were approximately the same whichever 
method was used to calculate them (Table III), and steroid 
depots, as assessed by skin blanching on only 2 volunteers after 
s ubsequent occlusion, wE!re similar. However, statistical analysis 
(Tm/l0 values-Table II) showed differences between the so-
lutions (p = 0.05) . The most active preparation (E) was signifi-
can~ly more active than the others. It contains a high concen-
tratlOn of propylene glycol (70%) together with propylene car-
bonate and water. It is possible that the propylene glycol acts 
as a penetration enhancer for the steroid and thus increases its 
bioavailability and activity (Table III) . Propylene carbonate 
may act similarly and its absence in other formulations may 
partly account for their poorer performances. Solution A has 
even more propylene glycol (86%) but it lacks water and pro-
pyJene carbonate. Thus it is possible that this absence and the 
irritant effect of such a high concentration of propylene glycol, 
together with its dehydration action on the stratum corneum, 
may overwhelm its accelerant action. Solution F is composed 
of 80% propylene glycol, 20% polyethylene glycol 400, and no 
water or propylene carbonate, and the solution is at the lower 
end of the scale of activity. We can postulate that the PEG 400 
hy~r?ge~ bonds t~ the steroid, so reducing its thermodynamic 
actIvity m the vehicle and therefore decreasing the steroid flux 
into the skin. Such an effect has been noticed with othel· 
steroids (B. J. Poulsen, personal communication). The conse-
quent diminution in r esponse would then be additional to the 
reductions caused by the irritant and dehydrating effects of the 
propylene glycol and the absence of propylene carbonate. 
We can conclude from this discussion that ow· consideration 
of thermodynamic effects is complicated by the fact that the 
diffusion model assumed may not be valid, in particular the 
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solvent components are probably not inert, i.e., they may act as 
enhancers, irritants, dehydrating agents, or t hey may bind the 
drug. Thus, we can suggest that model assumptions (iii) , (iv), 
and (ix) , in particular, were violated during our test procedure . 
. A. simpler picture should arise if we were to compare only 
SImilar solvent systems. Such formulations would use the same 
solvents (but in slightly different ratios) to attempt to maintain 
constant the thermodynamic activity of the steroid while the 
overall concentration of the drug differs. This was the philoso-
phy inherent in the formulation and testing of the second series 
of preparations, the 0.1% and 0.2% steroid gels. 
Fig 2 illustrates the characteristic blanching respo·nse for the 
gels, with sin1ilar activity rankings whether based on area under 
the curve or summed percent total possible score (Table IV) or 
bioavailability (Table V). The most pharmacologichlly active 
formulations were those of type E, composed of propylene 
glycol, propylene carbonate, and water, as was found in the fIrst 
phase of this study using solutions. Type F formulations were 
improved compared to the simple solution by including the 
emollient, surface active glycerol stearate (glycerol monostear-
ate). Within any solvent system, there was no signifIcant differ-
ence between gels containing different concentrations of ste-
roid, (p = 0.05). This observation accords with th ermodynamic 
~redictions on the b~si.s that secondary effects, such as p·enetra-
bon enhancement, Irntancy, dehydration, binding, etc., would 
be approximately constant within anyone solvent system. 
We can make the additional conclusion that the vasoconstric-
tor assay is a sensitive in vivo test in humans for assessing 
bioph~·maceutical factors in percutaneous absorption. 
A fmal remark may be appropriate. When we attempt to 
treat the complex process of percutaneous absorption in terms 
of a simple physicochemical model, the limitations and assump-
tions that we must impose are extensive (see above). The 
su~·pri~~ !s not how often our model fails to predict the bioa-
vailablhbes of drugs and their consequent therapeutic activities, 
but how often we can correlate physicochemical theory with 
biologic activity. .. 
The authors thank the Schering Corporation for support and for 
making the test formulations available. 
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